SCHEMBL424331

SCHEMBL424331

CN1CCN(C(=O)c2cnc(Cl)cn2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
HRH4 Q9H3N8 4/20 0.48
HRH3 Q9Y5N1 3/20 0.48
SIRT6 Q8N6T7 1/20 0.47
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
KMT2A Q03164 2/20 0.44
HSP90AA1 P07900 1/20 0.44
LMNA P02545 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
TSHR P16473 1/20 0.44
ALDH1A1 P00352 1/20 0.44
KDM4C Q9H3R0 1/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
HPGD P15428 1/20 0.41
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL320648 0.85 SIRT6 (0.52) HRH3SIRT6RAB9ANPC1SMN1; SMN2
SCHEMBL1725086 0.85 SIRT6 (0.52) POLBHRH3SIRT6RAB9ANPC1
SCHEMBL13779974 0.83 ALDH1A1 (0.51) POLBHRH4HRH3RAB9ANPC1
SCHEMBL1722269 0.81 SMN1; SMN2 (0.59) HRH3SIRT6RAB9ANPC1SMN1; SMN2
SCHEMBL3294698 0.80 POLB (0.55) POLBRAB9ASMN1; SMN2KMT2ALMNA
SCHEMBL16973643 0.78 PRKAA2 (0.46) HRH3SIRT6RAB9ASMN1; SMN2KMT2A
SCHEMBL16973768 0.77 SCN7A (0.43) HRH3SIRT6RAB9ASMN1; SMN2KMT2A
SCHEMBL712714 0.76 RAB9A (0.68) POLBHRH3RAB9ANPC1SMN1; SMN2
SCHEMBL12814065 0.76 HRH4 (0.50) POLBHRH4HRH3RAB9ANPC1
SCHEMBL13772554 0.75 CYP3A4 (0.63) POLBHRH4LMNAALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 US disclosed
WO-2022011337-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 WO disclosed
WO-2022011338-A2 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2022-01-13 WO disclosed
WO-2017182418-A1 CONJUGATES COMPRISING RIPK2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-10-26 WO disclosed
EP-2239253-B1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2013-06-19 EP disclosed
US-8415359-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2013-04-09 US disclosed
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-01-26 US disclosed
US-8017610-B2 Phenylpyrrole derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-09-13 US disclosed
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE DAIICHI SANKYO COMPANY, LIMITED (JP) 2011-01-06 US disclosed
EP-2239253-A1 NOVEL PHENYLPYRROLE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2010-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 POLB 1388/4885HRH4 1156/4885HRH3 912/4885
US-20110003787-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 POLB 4619/4885HRH4 1231/4885HRH3 1823/4885
US-20120022075-A1 NOVEL PHENYLPYRROLE DERIVATIVE GCKR, GCK, SLC5A1 POLB 4619/4885HRH4 1231/4885HRH3 1823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.